Alirocumab: A review in hypercholesterolemia

American Journal of Cardiovascular Drugs

Volumn 16, Issue 2, 2016, Pages 141-152

  Greig, Sarah L ^a   Deeks, Emma D ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; MONOCLONAL ANTIBODY;

ACUTE RESPIRATORY FAILURE; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ASTHMA; ATAXIA; CONCENTRATION AT STEADY-STATE; CREATINE KINASE BLOOD LEVEL; DEMYELINATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TOLERANCE; DYSARTHRIA; DYSLIPIDEMIA; ELIMINATION HALF-LIFE; FAMILIAL HYPERCHOLESTEROLEMIA; GUILLAIN BARRE SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LARYNX EDEMA; LEUKOCYTOCLASTIC VASCULITIS; MONOTHERAPY; MUSCLE FATIGUE; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL STIFFNESS; MYALGIA; OPTIC NEURITIS; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN ALLERGY; TREATMENT DURATION; TREATMENT INDICATION; BLOOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84959536990     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-016-0166-3     Document Type: Review

References (44)

1. Okere AN, Serra C. Evaluation of the potential role of alirocumab in the management of hypercholesterolemia in patients with highrisk cardiovascular disease. Pharmacotherapy. 2015;35(8): 771-9.
2. Urban D, Pöss J, Böhm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16): 1401-8.
3. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9(2): 129-69.
4. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14): 1769-818.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B): 2889-934.
6. Shimada YJ, Cannon CP. PCSK9 (proprotein convertase subtilisin/ kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36): 2415-24.
7. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15(3):[article no. 310].
8. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228(1): 18-28.
9. Sanofi-Aventis Groupe. Praluent solution for injection: EU summary of product characteristics. 2015. http://www.ema. europa.eu. Accessed 11 Feb 2016.
10. Regeneron Pharmaceuticals Inc, Sanofi-Aventis US LLC. Praluent (alirocumab) injection, for subcutaneous use: US prescribing information. 2015. http://www.fda.gov. Accessed 11 Feb 2016.
11. Kühnast S, van der Hoorn JWA, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10): 2103-12.
12. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12): 1108-18.
13. Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6): 297-301.
14. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16): 1489-99.
15. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20): 1891-900.
16. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25): 2344-53.
17. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836): 29-36.
18. Teramoto T, Kobayashi M, Uno K, et al. Efficacy and safety of alirocumab in Japanese patients with hypercholesterolemia on stable statin therapy: first data with the 75 mg every two weeks dose [abstract no. 13651]. Circulation. 2014;124(21 Suppl 1
19. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1): 55-61.
20. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6): 906-15.e13.
21. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19): 1186-94.
22. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8): 3140-8.
23. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244: 138-46.
24. Ginsberg HN, Rader DJ, Raal FJ, et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia [abstract no. CS.05 plus slides]. In: 87th Annual Scientific Sessions of the American Heart Association; 2014.
25. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43): 2996-3003.
26. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin-re-challenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6): 758-69.
27. Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28(3): 281-9.
28. Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014;37(10): 597-604.
29. Farnier M, Gaudet D, Valcheva V, et al. Efficacy of alirocumab in heterozygous familial hypercholesterolemia or high CV risk populations: pooled analyses of eight phase 3 trials [abstract no. EAS-0563]. Atherosclerosis. 2015;241(1): e25-6.
30. Taskinen M-R, Cannon CP, Thompson D, et al. Consistent reductions in atherogenic lipid parameters with the PCSK9 inhibitor alirocumab in patients not receiving background statin [abstract no. P6427]. Eur Heart J. 2015;36(Suppl 1): 1141.
31. Bays HE, Leiter LA, Colhoun HM, et al. Alirocumab treatment effect on non-HDL-C: pooled analyses of 10 phase 3 trials in the ODYSSEY program [abstract no. 183]. J Clin Lipidol. 2015;9(3): 471-2.
32. Gaudet D, Watts GF, Robinson JG, et al. Sustained treatment effect of alirocumab on Lp(a): pooled analyses from 4,915 patients in ten phase 3 trials in the ODYSSEY program [abstract no. P5980]. Eur Heart J. 2015;36(Suppl 1): 1047.
33. Bruckert E, Kereiakes DJ, Koren MJ, et al. Alirocumab leads to similar LDL-C reduction in 4812 patients (from nine phase 3 trials) with and without prior MI/ischemic stroke [abstract no. 327]. In: 17th International Symposium on Atherosclerosis; 2015.
34. Hovingh K, Ceska R, Louie MJ, et al. Alirocumab treatment effect did not differ between patients with/without low LDL-C or high triglyceride baseline levels in phase 3 trials [abstract no. 326]. In: 17th International Symposium on Atherosclerosis; 2015.
35. Jones PH, Bays H, Chaudhari U, et al. Pooled safety and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical trials of alirocumab [abstract no. 914-08]. J Am Coll Cardiol. 2015;65(10 Suppl): A1363.
36. Robinson J, Farnier M, Chaudhari U, et al. Adverse events in patients with low-density lipoprotein cholesterol levels <25 or <15 mg/dL on at least two consecutive visits in fourteen randomized, controlled, clinical trials of alirocumab [abstract no. 1164M-05 plus poster]. J Am Coll Cardiol. 2015;65(10 Suppl): A1350
37. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(Suppl): S1-122.e1.
38. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5): 682-9.
39. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8): 1411-6.
40. Amgen Europe BV. Repatha solution for injection: EU summary of product characteristics. 2015. http://ema.europa.eu. Accessed 11 Feb 2016.
41. Amgen Inc. Repatha (evolocumab) injection, for subcutaneous use: US prescribing information. 2015. http://www.fda.gov. Accessed 11 Feb 2016.
42. Roth EM, Rader DJ, Moriarty PM, et al. Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I [abstract no. 254]. In: 17th International Symposium on Atherosclerosis; 2015.
43. Stroes ES, Guyton JR, Lepor N, et al. Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study [abstract no. 269]. In: 17th International Symposium on Atherosclerosis; 2015.
44. Institute for Clinical and Economic Review. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and valuebased price benchmarks: final report. 2015. http://cepac.icerreview. org. Accessed 11 Feb 2016.